Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 17629360 | HLA-A*02 | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| induction of t-cell response by a dna vaccine encoding a novel hla-a*0201 severe acute respiratory syndrome coronavirus epitope. | |||||||
| 19050106 | HLA (HLA) | severe acute respiratory syndrome | NA | NA | NA | only_studied | |
| sixteen hla-dr0401- and 14 hla-dr0701-restricted epitopes within spike protein of severe acute respiratory syndrome-coronavirus (sars-cov) were identified. | |||||||
| 19445991 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | severe acute respiratory syndrome | Vietnamese | NA | NA | unclassified | |
| association of human leukocyte antigen class ii alleles with severe acute respiratory syndrome in the vietnamese population. | |||||||
| 19445991 | HLA (HLA) | emerging infectious diseases | Vietnamese | NA | NA | unclassified | |
| our results and accumulated data on hla in the asian populations would help in the understanding of associations with emerging infectious diseases. | |||||||
| 20709007 | HLA-A*02 | severe acute respiratory syndrome | NA | NA | NA | negation | |
| several human hla-a*0201 restricted ctl epitopes of severe acute respiratory syndrome (sars) spike (s) protein have been identified in hla-a*0201 transgenic (tg) mice, but the mechanisms and properties of immune responses are still not well understood. | |||||||
| 20844028 | HLA-A*24 | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| novel immunodominant peptide presentation strategy: a featured hla-a*2402-restricted cytotoxic t-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein. | |||||||
| 20844028 | HLA-A*24 | severe acute respiratory syndrome | NA | NA | NA | only_studied | |
| here, a severe acute respiratory syndrome coronavirus (sars-cov) nucleocapsid (n) protein-derived ctl epitope, n1 (qfkdnvill), restricted by hla-a*2402 was identified by a series of in vitro studies, including a computer-assisted algorithm for prediction, stabilization of the peptide by co-refolding with hla-a*2402 heavy chain and b(2)-microglobulin (b(2)m), and t2-a24 cell binding. | |||||||
| 20844028 | HLA-A*24 | severe acute respiratory syndrome | NA | NA | NA | only_studied | |
| here, a severe acute respiratory syndrome coronavirus (sars-cov) nucleocapsid (n) protein-derived ctl epitope, n1 (qfkdnvill), restricted by hla-a*2402 was identified by a series of in vitro studies, including a computer-assisted algorithm for prediction, stabilization of the peptide by co-refolding with hla-a*2402 heavy chain and b(2)-microglobulin (b(2)m), and t2-a24 cell binding. | |||||||
| 21745520 | HLA-A*02 | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| in the present study, we aimed to evaluate the immune responses of peptide-specific cd8(+) t cells induced by hla-a*0201 restricted severe acute respiratory syndrome-associated coronavirus (sars-cov) s epitopes plus cpg oligodeoxynucleotide (cpg odn), polyi:c and r848 as adjuvants. | |||||||
| 32693089 | MHC (MHC) | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| mortality in covid-19 disease patients: correlating the association of major histocompatibility complex (mhc) with severe acute respiratory syndrome 2 (sars-cov-2) variants. | |||||||
Copyright 2024